Biotechnology

As derivative lawsuits target biotech and industrial sectors, a new legal wave exposes the costly gap between high-tech corporate hype and operational reality.

Lamassu Biotech’s early ESMO data suggests its MDM2 inhibitor SA53 might finally bypass the class's notorious toxicities, opening a massive oncology market.

As Estrella Immunopharma's low-toxicity T-cell therapy enters its next clinical phase, a seasoned manufacturing executive takes the helm to scale operations.

TJ Biopharma has dosed the first patient in a Phase 1 trial for a novel CLDN6 bispecific antibody, aiming to overcome historical toxicity hurdles in oncology.

New Phase 2 data reveals Eledon's tegoprubart dramatically improves symptom burden and quality of life for kidney transplant patients versus standard care.

RyCarma's Phase 2 trial for RYR1-RM offers the first clinical hope for a neglected community, testing a novel mechanism that could reshape muscle disease care.

As Protalix prepares for the Stifel Healthcare Conference, its plant-based platform and growing royalties signal a shift toward sustainable profitability.

Atom Therapeutics is pivoting its gout asset to tackle a 435-million-patient CKD market. Will lingdolinurad succeed where past URAT1 inhibitors failed?

LivingPHOENIX claims to have solved the terminal sterilization bottleneck for synthetic collagen. David Patterson examines the tech, IP, and execution strategy.

Hansa Biopharma's enzyme therapy shows a 90% graft survival rate at one year, offering a vital lifeline to highly sensitized kidney patients ahead of FDA review.

By demonstrating unprecedented survival benefits regardless of biomarker expression, Genmab's Rina-S is poised to rewrite the rules of ovarian cancer treatment.

A new peer-reviewed study details how a single-entity lipid conjugate could replace complex LNPs and AOCs in extrahepatic genetic medicine.

Celebrating its 40th anniversary, Angel Yeast is leveraging its massive global infrastructure to conquer the synthetic biology and biomanufacturing sectors.

Phase 3 data at ASN Kidney Week reveals lorundrostat's ability to lower blood pressure and albuminuria, positioning Mineralys for a pivotal FDA decision.

Ahead of BIO-Europe 2026, South Korean biotech ImmunoForge leverages proprietary delivery platforms to tackle drug resistance and BBB limitations.

As Agenus prepares for its Q3 2026 earnings, the biotech firm is leveraging new capital and an Armenian approval to target treatment-resistant colon cancer.

Warhound is merging genetics and defense tech to rebuild America's working dog supply. But can cloning and cybernetics solve the Pentagon's canine crisis?

SenesTech posted its highest quarterly revenue ever. So why is the rodent birth control pioneer facing a Nasdaq delisting and an activist intervention?

As ProKidney prepares to unpack new clinical data, we examine the strategic and commercial realities of bringing cell therapy to chronic kidney disease.

As a 167-week-old mouse named Speedy becomes the unlikely face of geroscience, Eos SENOLYTIX leverages preclinical longevity data to challenge GLP-1s and court Wall Street.